- Conditions
- Rheumatoid Arthritis
- Interventions
- M2591 25 mg QD, M2951 75 mg QD, M2951 50 mg BID, Placebo
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • San Leandro, California • DeBary, Florida + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Rheumatoid Arthritis
- Interventions
- Placebo, M2951
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Billerica, Massachusetts
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Teriflunomide, Evobrutinib
- Drug
- Lead sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 38
- States / cities
- Cullman, Alabama • Scottsdale, Arizona • Tucson, Arizona + 34 more
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- Evobrutinib, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Rockland, Massachusetts
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Placebo, M2951
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 42
- States / cities
- Anniston, Alabama • Mesa, Arizona • Phoenix, Arizona + 37 more
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- Evobrutinib, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Rockland, Massachusetts
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Teriflunomide, Evobrutinib
- Drug
- Lead sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 51
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Long Beach, California + 44 more
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- MSC2364447C, Placebo
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 10
- States / cities
- Anniston, Alabama • El Cajon, California • Lakewood, California + 7 more